Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

144 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Patients' perspectives on the definition of cure in chronic myeloid leukemia.
Flynn KE, Mauro MJ, George G, Hinman A, Baim A, Kota V, Larson RA, Lipton JH, Thompson JE, Wadleigh M, Atallah E. Flynn KE, et al. Among authors: mauro mj. Leuk Res. 2019 May;80:40-42. doi: 10.1016/j.leukres.2019.03.007. Epub 2019 Mar 28. Leuk Res. 2019. PMID: 30955853 No abstract available.
An activating KRAS mutation in imatinib-resistant chronic myeloid leukemia.
Agarwal A, Eide CA, Harlow A, Corbin AS, Mauro MJ, Druker BJ, Corless CL, Heinrich MC, Deininger MW. Agarwal A, et al. Among authors: mauro mj. Leukemia. 2008 Dec;22(12):2269-72. doi: 10.1038/leu.2008.124. Epub 2008 May 29. Leukemia. 2008. PMID: 18509354 No abstract available.
Current practices in the management of chronic myeloid leukemia.
Kantarjian HM, Larson RA, Cortés JE, Deering KL, Mauro MJ. Kantarjian HM, et al. Among authors: mauro mj. Clin Lymphoma Myeloma Leuk. 2013 Feb;13(1):48-54. doi: 10.1016/j.clml.2012.07.009. Epub 2012 Oct 25. Clin Lymphoma Myeloma Leuk. 2013. PMID: 23103085 Free PMC article.
Evaluating the Impact of a Switch to Nilotinib on Imatinib-Related Chronic Low-Grade Adverse Events in Patients With CML-CP: The ENRICH Study.
Cortes JE, Lipton JH, Miller CB, Busque L, Akard LP, Pinilla-Ibarz J, Keir C, Warsi G, Lin FP, Mauro MJ. Cortes JE, et al. Among authors: mauro mj. Clin Lymphoma Myeloma Leuk. 2016 May;16(5):286-96. doi: 10.1016/j.clml.2016.02.002. Epub 2016 Feb 16. Clin Lymphoma Myeloma Leuk. 2016. PMID: 26993758 Free PMC article. Clinical Trial.
Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia.
Atallah E, Schiffer CA, Weinfurt KP, Zhang MJ, Radich JP, Oehler VG, Pinilla-Ibarz J, Deininger MWN, Lin L, Larson RA, Mauro MJ, Moore JO, Ritchie EK, Shah NP, Silver RT, Wadleigh M, Cortes J, Thompson J, Guhl J, Horowitz MM, Flynn KE. Atallah E, et al. Among authors: mauro mj. BMC Cancer. 2018 Apr 2;18(1):359. doi: 10.1186/s12885-018-4273-1. BMC Cancer. 2018. PMID: 29609532 Free PMC article.
Rates of deep molecular response by digital and conventional PCR with frontline nilotinib in newly diagnosed chronic myeloid leukemia: a landmark analysis.
Berdeja JG, Heinrich MC, Dakhil SR, Goldberg SL, Wadleigh M, Kuriakose P, Cortes J, Radich J, Helton B, Rizzieri D, Paley C, Dautaj I, Mauro MJ. Berdeja JG, et al. Among authors: mauro mj. Leuk Lymphoma. 2019 Oct;60(10):2384-2393. doi: 10.1080/10428194.2019.1590569. Epub 2019 Mar 26. Leuk Lymphoma. 2019. PMID: 30912699
144 results